Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Octreotide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    119 result(s) found for: Octreotide. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2010-023347-14 Sponsor Protocol Number: 2010-10 Start Date*: 2011-03-02
    Sponsor Name:Gastroenterology CHC Liege
    Full Title: Treatment of Crohn’s disease-associated refractory diarrhoea with octreotide LAR An open pilot study
    Medical condition: Crohn Disease refractory diarrhoea
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066533 Diarrhea recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003856-30 Sponsor Protocol Number: CSMS995ABE12T Start Date*: 2016-01-28
    Sponsor Name:Cliniques Universitaires Saint Luc
    Full Title: Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syn...
    Medical condition: The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreoti...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002603-13 Sponsor Protocol Number: 200601 Start Date*: 2006-10-24
    Sponsor Name:Leiden University Medical Center
    Full Title: Is treatment with octreotide effective in patients with head-and-neck paraganglioma?
    Medical condition: Patients with head-and-neck paraganglioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003496-20 Sponsor Protocol Number: LAR/005 Start Date*: 2006-10-31
    Sponsor Name:Oxford Radcliffe Hospitals NHS trust
    Full Title: The effect of pre-operative Octreotide LAR treatment on surgical cure rates of subjects with Acromegaly, and post-operative responsiveness to somatostatin analogue treatment in patients not cured s...
    Medical condition: Acromegaly, overproduction of growth hormone by (almost always) a benign pituitary tumour.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000849-40 Sponsor Protocol Number: HS-19-657 Start Date*: 2021-08-23
    Sponsor Name:Camurus AB
    Full Title: A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patie...
    Medical condition: gastroenteropancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) HU (Ongoing) DE (Ongoing) NL (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004032-19 Sponsor Protocol Number: NLOCEAN.505.14 Start Date*: 2015-09-09
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomised, open-label clinical trial assessing the efficacy of octreotide to decrease iron infusion and blood transfusion requirements in patients with refractory anaemia due to gastrointestinal...
    Medical condition: small bowel angiodysplasias
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002190-66 Sponsor Protocol Number: HS-19-647 Start Date*: 2019-07-12
    Sponsor Name:Camurus AB
    Full Title: A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) ES (Ongoing) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001200-38 Sponsor Protocol Number: OTIS2019_001 Start Date*: 2020-11-17
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Octreotide treatment to improve nutritional recovery after surgery for patients with esophageal or gastric cancer, a prospective randomized open label phase II study - OTIS
    Medical condition: Undesired weight loss after operation for esophageal or gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10027415 Metabolic abnormality management PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001191-11 Sponsor Protocol Number: HS-18-633 Start Date*: 2020-02-13
    Sponsor Name:Camurus AB
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001340-19 Sponsor Protocol Number: NLROW.1012.15 Start Date*: 2016-07-21
    Sponsor Name:Radboud University Medical Center
    Full Title: An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding
    Medical condition: Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002854-11 Sponsor Protocol Number: OOC-ACM-302 Start Date*: 2016-04-18
    Sponsor Name:Chiasma, Inc.
    Full Title: A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE MAINTENANCE OF RESPONSE, SAFETY AND PATIENT REPORTED OUTCOMES IN ACROMEGALY PATIENTS TREATED WITH OCTREOTIDE CAPS...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) RO (Completed) LT (Completed) DE (Completed) NL (Prematurely Ended) ES (Completed) AT (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000739-25 Sponsor Protocol Number: CSOM230C2303 Start Date*: 2008-01-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately contr...
    Medical condition: Metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007271 Carcinoid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) DE (Completed) IT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) BE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003183-31 Sponsor Protocol Number: DSC/13/2984/05 Start Date*: 2014-02-25
    Sponsor Name:ITALFARMACO S.p.A.
    Full Title: A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients.
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006889-29 Sponsor Protocol Number: MEC-2008-322 Start Date*: 2009-02-25
    Sponsor Name:ErasmusMC
    Full Title: A pilotstudy comparing systemic versus locoregional injection of radiolabelled somatostatin analogues in patients with neuroendocrine Gastro-Entero_Pancreatic (GEP) tumors.
    Medical condition: Uptake of Octreoscan in sst-2 receptor positive Gastro Entero Pancreatic neuroendocrine tumors injected in systemical and locoregional way.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005049-11 Sponsor Protocol Number: AAA-III-01 Start Date*: 2012-04-25
    Sponsor Name:Advanced Accelerator Applications
    Full Title: A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperabl...
    Medical condition: Patients with inoperable, progressive, OctreoScan® positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours), who are treated with 20 mg or 30 mg Octreotide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062392 Carcinoid tumor of the small bowel LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) PT (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000737-31 Sponsor Protocol Number: OOC-ACM-303 Start Date*: 2017-10-27
    Sponsor Name:Chiasma, Inc.
    Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical c...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) PL (Completed) IT (Completed) BG (Completed) LV (Completed) SI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-004328-39 Sponsor Protocol Number: INFUTER Start Date*: 2020-04-13
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica_FCRB
    Full Title: Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomised, single blinded clinical trial.
    Medical condition: The proposed study aims to investigate the hemodynamic effects of terlipressin and the time profile of these effects in patients with cirrhosis and portal hypertension when given as continuous infu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000549-15 Sponsor Protocol Number: S63678 Start Date*: 2020-08-05
    Sponsor Name:University Hospitals Leuven
    Full Title: Al18F-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors
    Medical condition: Neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003327-23 Sponsor Protocol Number: IP107-001 Start Date*: 2008-10-29
    Sponsor Name:Endo Pharmaceuticals Solutions Inc
    Full Title: PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-003764-27 Sponsor Protocol Number: HS-20-677 Start Date*: 2022-09-20
    Sponsor Name:Camurus AB
    Full Title: A randomized, placebo-controlled, double-blind, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease
    Medical condition: Polycystic liver disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA